American Pharmaceutical Companies Rapidly Acquire Licenses for Drugs from China
American pharmaceutical companies are rapidly acquiring licenses for drugs from Chinese companies to reduce research and development costs. In the first six months of the year, 14 such agreements were made, compared to only two last year, with a total value of up to $18.3 billion. This trend is driven by the need to replace…